<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05070728</url>
  </required_header>
  <id_info>
    <org_study_id>EYP-2102-001</org_study_id>
    <nct_id>NCT05070728</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI)</brief_title>
  <official_title>A Phase 3, Multicenter, Prospective, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide (FA) Intravitreal 0.05 mg Insert (Yutiq 0.05 mg) in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EyePoint Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EyePoint Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the safety and efficacy of an FAI insert for the management of subjects&#xD;
      with non-infectious uveitis affecting the posterior segment of the eye.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3, multi-center, randomized, masked, controlled study to evaluate the safety&#xD;
      and efficacy of an injectable fluocinolone acetonide intravitreal (FAI) insert for the&#xD;
      management of subjects with non-infectious uveitis affecting the posterior segment of the&#xD;
      eye. Patients will be randomized to receive either a sham injection or the FAI insert and&#xD;
      will be observed for one year following treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who have a recurrence of uveitis in the study eye within 24 weeks (6 months) after receiving study treatment</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Uveitis</condition>
  <condition>Uveitis, Posterior</condition>
  <condition>Uveitis, Intermediate</condition>
  <arm_group>
    <arm_group_label>Sham Comparator</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sham injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FAI insert (0.05 mg fluocinolone acetonide)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FAI insert (0.05 mg fluocinolone acetonide)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham Injector</intervention_name>
    <description>Sham injection</description>
    <arm_group_label>Sham Comparator</arm_group_label>
    <other_name>Sham Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FAI Insert</intervention_name>
    <description>FAI insert</description>
    <arm_group_label>FAI insert (0.05 mg fluocinolone acetonide)</arm_group_label>
    <other_name>Active Drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant female at least 18 years of age at time of consent&#xD;
&#xD;
          -  One or both eyes having a history of recurrent non-infectious uveitis affecting the&#xD;
             posterior segment of the eye (intermediate, posterior, or panuveitis) with or without&#xD;
             anterior uveitis &gt; 1 year duration.&#xD;
&#xD;
          -  During the 52 weeks prior to enrollment (Day 1), the study eye has either received&#xD;
             treatment systemic corticosteroid or other systemic therapies given for at least 12&#xD;
             weeks, and/or at least 2 intra- or peri-ocular injections of corticosteroid for&#xD;
             management of uveitis OR the study eye has experienced recurrence recurrences of&#xD;
             uveitis at least 2 separate times requiring systemic, intra- or peri-ocular injection&#xD;
             of corticosteroid.&#xD;
&#xD;
          -  Subject is not planning to undergo elective ocular surgery during the study&#xD;
&#xD;
          -  Subject has ability to understand and sign the Informed Consent Form (ICF).&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plan, laboratory&#xD;
             tests, and other study procedures.&#xD;
&#xD;
          -  Other protocol-specified inclusion criteria may apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of posterior uveitis only that is not accompanied by vitritis or macular&#xD;
             edema.&#xD;
&#xD;
          -  History of iritis only associated with no vitreous cells, anterior chamber cells, or&#xD;
             vitreous haze at Day 1.&#xD;
&#xD;
          -  Uveitis with infectious etiology.&#xD;
&#xD;
          -  Vitreous hemorrhage.&#xD;
&#xD;
          -  Intraocular inflammation associated with a condition other than noninfectious uveitis&#xD;
             (eg, intraocular lymphoma).&#xD;
&#xD;
          -  Uveitis limited to the anterior segment, ie, anterior uveitis only.&#xD;
&#xD;
          -  Ocular malignancy in either eye, including choroidal melanoma.&#xD;
&#xD;
          -  Previous viral retinitis.&#xD;
&#xD;
          -  Requirement for chronic systemic or inhaled corticosteroid therapy (&gt;15mg prednisone&#xD;
             daily) or chronic systemic immunosuppressive therapy.&#xD;
&#xD;
          -  History of certain skin cancers (specifically, basal cell carcinoma and squamous cell&#xD;
             carcinoma), any malignancy receiving treatment, or in remission less than 5 years&#xD;
             prior to Day 1.&#xD;
&#xD;
          -  Positive test for human immunodeficiency virus (HIV) or syphilis during Screening.&#xD;
&#xD;
          -  Mycobacterial uveitis or chorioretinal changes of either eye which, in the opinion of&#xD;
             the Investigator, result from infectious mycobacterial uveitis.&#xD;
&#xD;
          -  Systemic infection within 30 days prior to Day 1.&#xD;
&#xD;
          -  Pregnant or nursing females; females of childbearing potential who are unwilling or&#xD;
             unable to use an acceptable method of contraception as outlined in the protocol from&#xD;
             at least 14 days prior to Day 1 until the 52-week Visit.&#xD;
&#xD;
          -  Other protocol-specified exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dario Paggiarino, MD</last_name>
    <phone>617-610-3411</phone>
    <email>dpaggiarino@eyepointpharma.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EYP-2102</keyword>
  <keyword>EyePoint</keyword>
  <keyword>Uveitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Uveitis, Posterior</mesh_term>
    <mesh_term>Uveitis, Intermediate</mesh_term>
    <mesh_term>Pars Planitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

